As a new anti-tumor strategy, PEM+EV ranked first in this NMA with absolute advantages in OS, PFS, and ORR data, and the results of the EV-302 study subgroup confirmed that it can benefit regardless of cisplatin tolerance and PD-L1 expression level (13). The gene discussed is CD274; the disease is neoplasm.